A study offers promising news for young women with early-stage breast cancer who want to have children after treatment, showing that 73% of breast cancer survivors who attempted pregnancy were successful.
A study presented at a press event ahead of the American Society of Clinical Oncology (ASCO) Annual Meeting shows high success rates for pregnancy after treatment. Among patients with stages I to III breast cancer who attempted to conceive, 73% were able to achieve pregnancy and deliver a live birth. However, the study also suggests certain factors may influence pregnancy success.
“The current research that informs our understanding of the impact of breast cancer treatment on pregnancy and life birth rates is fairly limited,” study author Kimia Sorouri, MD, MPH, said in a presentation of the data. “This is the first prospective study with greater than 10 years of follow-up to report fertility outcomes in young breast cancer survivors account for attempting pregnancy.”
Sorouri is a member of the Breast Oncology Program at the Dana-Farber Cancer Institute in Boston.
“Many young women who are diagnosed with breast cancer are interested in future fertility,” Sorouri said. “However, many cancer treatments can impair an individual’s fertility and their ability to carry a pregnancy.”
Researchers on the study analyzed data from the prospective Young Women’s Breast Cancer Study. There were 1,213 patients aged 40 years and younger who received a diagnosis of stage 0 to stage III breast cancer between the years 2006 and 2016. Of note, patients with metastatic disease or who had their uterus or ovaries removed were not included in the study.
Among these participants, 197 reported that they attempted pregnancy over a median follow-up of 11 years. In this group, 73% became pregnant at least once, with 90% of these patients reporting having at least one pregnancy that resulted in a live birth. The median time to diagnosis to the first pregnancy was 48 months, according to the data, and among the 197 women who reported pregnancies, the median age at their breast cancer diagnosis was 32 years.
Of the 197 patients who attempted to conceive after their diagnosis, about half of patients (51%) reported being financially comfortable, and 72% reported never having a live birth before diagnosis. A total of 28% of patients underwent fertility preservation (via cryopreservation of embryos and/or eggs). In addition, 15% of patients had a known history of infertility before receiving their breast cancer diagnosis.
Regarding disease and treatment history of those who became pregnant, the majority (76%) had ER- and/or PR-positive disease, followed by HER2-positive disease (25%) and triple-negative breast cancer (17%).
Sixty-eight percent of patients received chemotherapy; 57% received endocrine therapy; 58% received radiation; 38% underwent a lumpectomy (surgical removal of part of the breast tissue to remove cancer); 22% underwent a unilateral mastectomy (surgical removal of one breast); and 41% underwent a bilateral mastectomy (surgical removal of both breasts).
Data showed that factors associated with a higher chance of becoming pregnant included: being younger at the time of diagnosis; being financially comfortable, defined as still having enough money left over to “buy special things after paying bills”; having undergone fertility preservation.
“While having undergone fertility preservation at diagnosis prior to receiving their cancer treatment was predictive of a live birth, the other patient cancer and treatment factors collected are not associated with either outcome,” Sorouri said.
The researchers also uncovered factors that did not seem to have an impact on the chance of pregnancy or birth. They were:
“This suggests that in this modern cohort with a heightened awareness of fertility, access to fertility preservation can help to mitigate a portion of the damage from chemotherapy and other agents,” Sorouri said. “Importantly, this highlights the need for increased accessibility of fertility preservation services for women newly diagnosed with breast cancer who are interested in a future pregnancy.”
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More